| Literature DB >> 29875144 |
Nidhi Khurana1, Sayan Bakshi2, Wahida Tabassum2, Mrinal K Bhattacharyya2, Sunanda Bhattacharyya3.
Abstract
Recent studies have demonstrated that aberrant sister chromatid cohesion causes genomic instability and hence is responsible for the development of a tumor. The Chl1 (chromosome loss 1) protein (homolog of human ChlRl/DDX11 helicase) plays an essential role in the proper segregation of chromosomes during mitosis. The helicase activity of Chl1 is critical for sister chromatid cohesion. Our study demonstrates that Hsp90 interacts with Chl1 and is necessary for its stability. We observe that the Hsp90 nonfunctional condition (temperature-sensitive iG170Dhsp82 strain at restrictive temperature) induces proteasomal degradation of Chl1. We have mapped the domains of Chl1 and identified that the presence of domains II, III, and IV is essential for efficient interaction with Hsp90. We have demonstrated that Hsp90 inhibitor 17-AAG (17-allylamino-geldenamycin) causes destabilization of Chl1 protein and enhances significant disruption of sister chromatid cohesion, which is comparable to that observed under the Δchl1 condition. Our study also revealed that 17-AAG treatment causes an increased frequency of chromosome loss to a similar extent as that of the Δchl1 cells. Hsp90 functional loss has been earlier linked to aneuploidy with very poor mechanistic insight. Our result identifies Chl1 as a novel client of Hsp90, which could be further explored to gain mechanistic insight into aneuploidy.IMPORTANCE Recently, Hsp90 functional loss has been linked to aneuploidy; however, until now none of the components of sister chromatid cohesion (SCC) have been demonstrated as the putative clients of Hsp90. In this study, we have established that Chl1, the protein which is involved in maintaining sister chromatid cohesion as well as in preventing chromosome loss, is a direct client of Hsp90. Thus, with understanding of the molecular mechanism, how Hsp90 controls the cohesion machinery might reveal new insights which can be exploited further for attenuation of tumorigenesis.Entities:
Keywords: Chl1; Hsp90; chromosome segregation; sister chromatid cohesion
Mesh:
Substances:
Year: 2018 PMID: 29875144 PMCID: PMC5990887 DOI: 10.1128/mSphere.00225-18
Source DB: PubMed Journal: mSphere ISSN: 2379-5042 Impact factor: 4.389
FIG 1 Inhibition of Hsp90 function causes destabilization of Chl1 and promotes its proteasomal degradation. (A) Western blot analysis shows the steady-state levels of Chl1 under single-knockout conditions of either form of yHsp90. Actin acts as a loading control. WT, wild type. (B) Quantification of the band intensities shows that Chl1 level remains unchanged under the conditions mentioned above. The band intensities in each lane are normalized against actin, and mean densities ± SDs are plotted. N.S., not significant. (C) Western blots revealing the effect of 17-AAG on the stability of Chl1 compared to the untreated condition. UT, untreated; T, treated. (D) Quantification of the band intensities from three different experiments displays 3-fold reductions in the level of Chl1 upon loss of function of Hsp90. The band intensities are normalized against actin, and mean densities ± SDs are plotted. (E) Semiquantitative reverse transcription-PCR analysis showing no effect on CHL1 transcript levels under 17-AAG-treated condition normalized against ACTIN. (F) Western blot analysis showing the reaccumulation of Chl1 upon the inhibition of the proteasome degradation pathway when Hsp90 is nonfunctional. The experiment was carried out in a temperature-sensitive strain at permissive and restrictive temperatures. Levels of Hsp90 remain unaffected owing to its regulation under the noninducible GPD promoter. (G) Semiquantitative reverse transcription-PCR analysis showing no effect on CHL1 transcript levels under permissive and restrictive temperatures normalized against ACTIN.
FIG 2 Hsp90 physically interacts with Chl1. (A) Coimmunoprecipitation data showing the interaction of Hsp90 with Chl1. The pulldown assay was performed with anti-Hsp90 antibody as well as with preimmune sera, and the assay mixture was immunoblotted with anti-Myc antibody to probe Chl1. IP, immunoprecipitate; SN, supernatant. (B) The right panels show yeast two-hybrid analysis exhibiting the extent of the interaction between Hsp90 and different constructs of Chl1. To study the protein-protein interaction, equal numbers of cells were serially diluted and spotted on medium lacking uracil, leucine, and histidine. The left panels show various combinations of bait and prey vectors. They show that all the strains are viable under normal conditions. In the right panels, growth is displayed only by the strains harboring Hsp90-bait vector and Chl1-prey vector, which indicates that interaction exists between these proteins. (C) Schematic representation of the domain organization of full-length Chl1 and different truncated versions created for interaction analysis with Hsp90. P, PEST sequences. (D) Interaction evaluated according to growth in triple dropout medium: strong (++), weak (+), or no (−) interaction.
FIG 3 Inhibition of Hsp90 function exhibits a defect in chromosome segregation to the same extent as that of the chl1 deletion mutant. (A) Schematic representation of the chromosome loss assay, indicating the possible outcome of different-color colonies. (B) Representative images of the colonies obtained. The black arrows indicate the colony with first-division chromosome loss; the yellow arrows show the colonies that are not considered for the analysis, as a fully red colony denotes chromosome loss before plating and a colony less than 50% red denotes chromosome loss later than the first division. (C) Bar graph showing fold change in chromosome loss frequency exhibited by the wild-type strain, Hsp90-inhibited strain, and Δchl1 strain. (D) Bar graph showing fold changes in chromosome loss frequency exhibited by the null chl1 strain harboring the truncated Chl1 (N-466) that blocks the interaction with Hsp90. The experiment was done in the presence of an isogenic positive control (null chl1 strain harboring full-length CHL1) and a negative control (the same strain harboring empty plasmid). The number of colonies showing first-division chromosome loss for each condition was obtained from three different sets of experiments. Error bars indicate SDs (n = 3). P values were calculated using the two-tailed Student t test; NS, not significant.
FIG 4 Inhibition of Hsp90 is associated with a reduction in sister chromatid cohesion. (A) Illustration of the principle behind the assay. The mRFP (monomeric red fluorescent protein) molecule fused with the Tet repressor indirectly labels the chromosome, which can be visualized under the confocal microscope. The cells are arrested with nocodazole at preanaphase. After duplication of chromosomes, if the sister chromatids are associated, then that will appear as one red focus, and if they are dissociated, then that will appear as either two distinct foci or one diffused focus. (B) Representative images for different strains (wild type, Δchl1, and 17-AAG treated) are shown. The top panel shows the cells in bright field. The second panel depicts the associated/dissociated sister chromatids marked by red foci which are indicated by yellow arrowheads in a single cell. The third panel shows the expression of Pds1p as marked by green fluorescence. The bottom panel shows the merged image. DIC, differential interference contrast. (C) Graph showing average percentage of cells displaying dissociated sister chromatids from three different sets of experiments. For each strain, at least 1,000 cells were counted. The error bars represent standard deviations. The Western blot panel at right confirms that Chl1 protein levels are diminished upon Hsp90 inhibition by 17-AAG treatment. UT, untreated; T, treated.
Primers used in this study
| Primer name | Sequence | Purpose |
|---|---|---|
| OSB 90 | 5′ CTG TGG ATC CAT GGA CAA AAA GGA ATA TTC 3′ | Forward primer used to amplify full-length |
| OSB 91 | 5′ CGA TGT CGA CTT AGC GTG AAT TCA GGC TGC 3′ | Reverse primer used to amplify full-length |
| OSB 78 | 5′ AAC ACG GAA GTT TTT TTC AAT GCG CAG CCT GAA | Forward primer used to generate |
| OSB 79 | 5′ ATA TAG TAG TAA TCA CAG TAT ACA CGT AAA CGT | Reverse primer used to generate |
| OSB 80 | 5′ CGG CAT GCA AAT GAT TAC GC 3′ | Forward primer used to confirm |
| OSB107 | 5′ GTA GAA AAC CAG GCT AAA AAC AGT CAC ACT | Forward primer used for |
| OSB 108 | 5′ ATA TAG TAG TAA TCA CAG TAT ACA CGT AAA CGT | Reverse primer used for |
| OSB 109 | 5′ CGT AAC CAC AGA GTT GAG GTA G 3′ | Forward primer used for |
| OMKB 411 | 5′ AAG TTT TCG TAT CCG CTC GTT CGA AAG ACT TTA | Forward primer used for |
| OMKB 412 | 5′ TCT TGG TAA GTT TCT TTT CTT AAC CAA ATT CAA | Reverse primer used for |
| OMKB 413 | 5′ AAG TCA CGC AAA GTT GCA AAC 3′ | Forward primer used for confirmation of |
| OSB 290 | 5′ CCG TAA TCA TTG ACC AGA GCC 3′ | Reverse primer used for confirmation |
| OSB 318 | 5′ CTG TTG AAC GTA ATC TGA GC 3′ | Forward primer used for |
| OSB 319 | 5′ TTC TCG GAA TTC TTT CGG AC 3′ | Reverse primer used for |
| OSB 160 | 5′ GGA AGA GGA AGC TTC ACG AG 3′ | Forward primer used to amplify |
| OSB 91 | 5′ TTA GCG TGA ATT CAG GCT GC 3′ | Reverse primer used to amplify |
| OSB 16 | 5′ TGA CCA AAC TAC TTA CAA CTC C 3′ | Forward primer used to amplify |
| OSB 14 | 5′ TTA GAA ACA CTT GTG GTG AAC G 3′ | Reverse primer used to amplify |
| OSB 381 | 5′ TAT TTC TTG TCC TAT CTT C 3′ | Reverse primer used to amplify N-466 of |
| OSB 382 | 5′ TCG AGA GAT CCA AAC AAT GGC 3′ | Forward primer used to amplify C-648 of |
| OSB 383 | 5′ TCG TGC AAT CAT GTT ATA CCG 3′ | Forward primer used to amplify C-253 of |
| OSB 384 | 5′ GTG AGG AAA ATA TTC TAT GAA GC 3′ | Forward primer used to amplify C-170 of |
Yeast strains used in this study
| Strain | Genotype | Source or reference |
|---|---|---|
| W303α | This study | |
| NKY39 | This study | |
| NKY40 | This study | |
| NKY41 | This study | |
| NKY43 | This study | |
| NKY2 | This study | |
| NKY3 | This study | |
| SLY89 | This study | |
| NKY45 | This study | |
| Gift from Santanu K. Ghosh | ||
| NKY4 | This study | |
| NKY9 | This study | |
| NKY61 | This study | |
| NKY62 | This study | |
| YMH58a | Gift from Akash Gunjan | |
| NKY46 | This study | |
| NKY47 | This study | |
| SBY1 | This study | |
| SBY2 | This study | |
| SBY3 | This study | |
| PJ69-4A | ||
| NKY48 | This study | |
| NKY49 | This study | |
| NKY50 | This study | |
| NKY51 | This study | |
| NKY52 | This study | |
| NKY53 | This study | |
| NKY54 | This study | |
| NKY55 | This study | |
| NKY56 | This study | |
| NKY57 | This study | |
| NKY58 | This study | |
| NKY59 | This study |